FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
RUBY Financial Statements
Year
2022
2021
2020
2019
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
127.25M
194.62M
166.45M
169.6M
Research and Development
96.41M
141.59M
116.11M
112.42M
Selling, General & Administrative Expenses
30.84M
53.03M
50.34M
57.18M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
30.84M
53.03M
50.34M
57.18M
Other Expenses
1.82M
-1.93M
-1.28M
6.14M
Operating Income
-178.45M
-194.62M
-166.45M
-169.6M
Total Other Income/Expenses Net
-1.22M
-1.93M
-1.28M
6.14M
Income Before Tax
-179.67M
-196.55M
-167.73M
-163.46M
Income Tax
51.2M
-7.72M
-5.69M
-3M
Net Income
-230.86M
-188.82M
-162.04M
-160.46M
Basic EPS
-2.56
-2.15
-2.01
-2.04
EPS Diluted
-2.56
-2.15
-2.01
-2.04
Basic Average Shares
90.31M
87.95M
80.62M
78.69M
Diluted Average Shares
90.31M
87.95M
80.62M
78.69M
EBITDA
-118.35M
-194.62M
-166.45M
-169.6M
All figures are in USD.
